Lundbeck's former head of North America appointed CEO of Capsida Biotherapeutics
Peter Anastasiou, who has spearheaded Danish pharmaceutical firm Lundbeck's operation in the US where he oversaw the launch of migraine drug Vyepti, has revealed the next step in his career on LinkedIn. In November, he announced his departure from Lundbeck.
by ulrich quistgaard
Lundbeck's departing head of North America, Peter Anastasiou, now reveals his new job title in a post on social media LinkedIn.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's CEO: Departing CFO is not defecting to competitor
For subscribers
Lundbeck's chief financial officer to exit before May 2022
For subscribers
Lundbeck appoints new chief commercial officer
For subscribers
